## Melissa L Mannion

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3456882/publications.pdf Version: 2024-02-01



MELISSA L MANNION

#	Article	IF	CITATIONS
1	A Rare STXBP2 Mutation in Severe COVID-19 and Secondary Cytokine Storm Syndrome. Life, 2022, 12, 149.	2.4	5
2	Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference. Journal of Rheumatology, 2022, 49, 497-503.	2.0	4
3	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis and Rheumatology, 2022, 74, 570-585.	5.6	11
4	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 553-569.	5.6	68
5	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research, 2022, 74, 505-520.	3.4	15
6	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 521-537.	3.4	27
7	Therapeutic strategies for treating juvenile idiopathic arthritis. Current Opinion in Pharmacology, 2022, 64, 102226.	3.5	10
8	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology, 2021, 48, 1322-1329.	2.0	10
9	Making Decisions About Stopping Medicines for Wellâ€Controlled Juvenile Idiopathic Arthritis: A Mixedâ€Methods Study of Patients and Caregivers. Arthritis Care and Research, 2021, 73, 374-385.	3.4	17
10	Distinguishing active pediatric COVID-19 pneumonia from MIS-C. Pediatric Rheumatology, 2021, 19, 21.	2.1	30
11	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	3.4	13
12	New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report. BMC Pediatrics, 2021, 21, 333.	1.7	24
13	Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis and Rheumatology, 2020, 72, 326-334.	5.6	197
14	Alagille Syndrome and Chronic Arthritis: An International Case Series. Journal of Pediatrics, 2020, 218, 228-230.e1.	1.8	5
15	Characteristics of coexisting localized scleroderma and inflammatory arthritis. European Journal of Rheumatology, 2020, 7, 67-71.	0.6	8
16	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology, 2019, 46, 1006-1013.	2.0	34
17	Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatric Rheumatology, 2018, 16, 71.	2.1	34
18	Defining the normal appearance of the temporomandibular joints by magnetic resonance imaging with contrast: a comparative study of children with and without juvenile idiopathic arthritis. Pediatric Rheumatology, 2018, 16, 8.	2.1	19

MELISSA L MANNION

#	Article	IF	CITATIONS
19	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1884-1888.	2.0	11
20	Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. Pediatric Rheumatology, 2017, 15, 79.	2.1	8
21	The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Research and Therapy, 2016, 18, 210.	3.5	34
22	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2016, 14, 49.	2.1	12
23	Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. Journal of Clinical Rheumatology, 2016, 22, 282-284.	0.9	19
24	Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors. Journal of Rheumatology, 2014, 41, 2078-2084.	2.0	16
25	Risk of malignancy associated with biologic agents in pediatric rheumatic disease. Current Opinion in Rheumatology, 2014, 26, 538-542.	4.3	15
26	What is the Background Incidence of Malignancy in Children with Rheumatic Disease?. Current Rheumatology Reports, 2013, 15, 310.	4.7	22
27	Brief Report: Incidence of Selected Opportunistic Infections Among Children With Juvenile Idiopathic Arthritis. Arthritis and Rheumatism, 2013, 65, 1384-1389.	6.7	53
28	Sarcoidosis in a young child with Alagille syndrome: a case report. Pediatric Rheumatology, 2012, 10, 32.	2.1	6
29	Successful treatment of pediatric IgG4 related systemic disease with mycophenolate mofetil: case report and a review of the pediatric autoimmune pancreatitis literature. Pediatric Rheumatology, 2011, 9, 1.	2.1	55
30	Brain cavernomas associated with en coup de sabre linear scleroderma: Two case reports. Pediatric Rheumatology, 2011, 9, 18.	2.1	26
31	Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. ACR Open Rheumatology, 0, , .	2.1	1